Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 5Genitourinary 3Gastrointestinal 3Sarcoma 2Gynecologic 2Thoracic 1Lymphoid 1Head & Neck 1CNS 1Breast 1

Conditions

Ovarian Neoplasms 13Uterine Cervical Neoplasms 9Stomach Neoplasms 9Colorectal Neoplasms 7Fallopian Tube Neoplasms 6Carcinoma, Ovarian Epithelial 6Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 5Endometrial Neoplasms 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Breast Neoplasms 4Prostatic Neoplasms 3Lung Neoplasms 3Esophageal Neoplasms 3Triple Negative Breast Neoplasms 2Sarcoma 2Rectal Neoplasms 2Neuroendocrine Tumors 2Melanoma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Appendiceal Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Recurrence 1Peritoneal Neoplasms 1

Interventions

pembrolizumab 49Nivolumab 22Cyclophosphamide 20fludarabine 13Paclitaxel 9Ipilimumab 9atezolizumab 8aldesleukin 8Specimen Handling 8Interleukin-2 7Carboplatin 7Magnetic Resonance Spectroscopy 6Docetaxel 6Biopsy 6cemiplimab 5fludarabine phosphate 4durvalumab 4Taxes 4Gemcitabine 4Drug Therapy 4spartalizumab 3poly ICLC 3epacadostat 3X-Rays 3Leucovorin 3Injections 3Immunoglobulin G 3Filgrastim 3Cisplatin 3CTLA-4 Antigen 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × Irinotecan × Gynecologic × Clear all
NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

Phase 1 Active not recruiting
138 enrolled
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡